According to the research report, the global autologous cell therapy market size is expected to touch USD 38.24 Billion by 2032, from USD 6.13 Billion in 2022, growing with a significant CAGR of 20.09% from 2023 to 2032.
The autologous cell therapy report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global autologous cell therapy in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global autologous cell therapy market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global autologous cell therapy during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2857
Report Scope of the Autologous Cell Therapy Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 7.36 Billion |
| Market Size by 2032 | USD 38.24 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 20.09% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Source, By Application, and By End-Use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This study covers a detailed segmentation of the global autologous cell therapy market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global autologous cell therapy market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Autolus Therapeutics
- Lineage Cell Therapeutics, Inc.
- Sangamo Therapeutics
- Holostem Terapie Avanzate S.r.l.
- Vericel Corporation
- Opexa Therapeutics
- BrainStorm Cell Therapeutics
- Pharmicell Co., Inc.
- Bayer AG
- Daiichi Sankyo Co., Ltd
- Takeda Pharmaceutical Co., Ltd
- Sumitomo Chemical Co., Ltd
- Immuneel Therapeutics
- Lonza
Market Segmentation
By Source
- Epidermis
- Bone Marrow
- Mesenchymal Stem Cells
- Haematopoietic Stem Cells
- Chondrocytes
- Others
By Application
- Cancer
- Cardiovascular Disorders
- Neurodegenerative Disorders
- Autoimmune Disorders
- Orthopedics
- Wound Healing
- Others
By End-Use
- Hospitals & Clinics
- Ambulatory Centers
- Academics & Research
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global autologous cell therapy report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global autologous cell therapy market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Autologous Cell Therapy Market
5.1. COVID-19 Landscape: Autologous Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Autologous Cell Therapy Market, By Source
8.1. Autologous Cell Therapy Market Revenue and Volume, by Source, 2023-2032
8.1.1 Epidermis
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Bone Marrow
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Mesenchymal Stem Cells
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Haematopoietic Stem Cells
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. Chondrocytes
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Autologous Cell Therapy Market, By Application
9.1. Autologous Cell Therapy Market Revenue and Volume, by Application, 2023-2032
9.1.1. Cancer
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Cardiovascular Disorders
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Neurodegenerative Disorders
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
9.1.4. Autoimmune Disorders
9.1.4.1. Market Revenue and Volume Forecast (2020-2032)
9.1.5. Orthopedics
9.1.5.1. Market Revenue and Volume Forecast (2020-2032)
9.1.6. Wound Healing
9.1.6.1. Market Revenue and Volume Forecast (2020-2032)
9.1.7. Others
9.1.7.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Autologous Cell Therapy Market, By End-Use
10.1. Autologous Cell Therapy Market Revenue and Volume, by End-Use, 2023-2032
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Ambulatory Centers
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Academics & Research
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Autologous Cell Therapy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.1.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Source (2020-2032)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Volume Forecast, by End-Use (2020-2032)
Chapter 12. Company Profiles
12.1. Autolus Therapeutics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Lineage Cell Therapeutics, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sangamo Therapeutics
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Holostem Terapie Avanzate S.r.l.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Vericel Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Opexa Therapeutics
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. BrainStorm Cell Therapeutics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Pharmicell Co., Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Bayer AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Daiichi Sankyo Co., Ltd
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments